Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E. Belshe RB, et al. Among authors: reisinger k. J Infect Dis. 2004 Feb 1;189(3):462-70. doi: 10.1086/381184. Epub 2004 Jan 20. J Infect Dis. 2004. PMID: 14745704 Clinical Trial.
A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM. Greenberg DP, et al. J Infect Dis. 2005 Apr 1;191(7):1116-22. doi: 10.1086/428092. Epub 2005 Feb 22. J Infect Dis. 2005. PMID: 15747247 Clinical Trial.
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M. Belshe RB, et al. Among authors: reisinger k. J Pediatr. 2000 Feb;136(2):168-75. doi: 10.1016/s0022-3476(00)70097-7. J Pediatr. 2000. PMID: 10657821 Clinical Trial.
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
Halperin SA, Eastwood B, Barreto L, Mills E, Blatter M, Reisinger K, Bader G, Keyserling H, Roberts EA, Guasparini R, et al. Halperin SA, et al. Among authors: reisinger k. Scand J Infect Dis. 1995;27(3):279-87. doi: 10.3109/00365549509019022. Scand J Infect Dis. 1995. PMID: 8539554 Clinical Trial.
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. King JC Jr, et al. Among authors: reisinger k. Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. Vaccine. 2009. PMID: 19716456 Clinical Trial.
Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine.
Frey S, Dagan R, Ashur Y, Chen XQ, Ibarra J, Kollaritsch H, Mazur MH, Poland GA, Reisinger K, Walter E, Van Damme P, Braconier JH, Uhnoo I, Wahl M, Blatter MM, Clements D, Greenberg D, Jacobson RM, Norrby SR, Rowe M, Shouval D, Simmons SS, van Hattum J, Wennerholm S, Gress JO, et al. Frey S, et al. Among authors: reisinger k. J Infect Dis. 1999 Dec;180(6):2018-22. doi: 10.1086/315119. J Infect Dis. 1999. PMID: 10558961 Clinical Trial.
198 results